Increased urinary leukotriene E4 concentration in patients with eosinophilic pneumonia

European Respiratory Journal

Volumn 32, Issue 2, 2008, Pages 437-442

  Ono, E ^a,b   Taniguchi, M ^a   Mita, H ^a   Higashi, N ^a   Fukutomi, Y ^a   Tanimoto, H ^a   Sekiya, K ^a   Oshikata, C ^a   Tsuburai, T ^a   Tsurikisawa, N ^a   Otomo, M ^a   Maeda, Y ^a   Matsuno, O ^b   Miyazaki, E ^b   Kumamoto, T ^b   Akiyama, K ^a  

^a SAGAMIHARA NATIONAL HOSPITAL   (Japan)

^b OITA UNIVERSITY   (Japan)

Author keywords

Biomarkers; Bronchial asthma; Diffusing capacity; Eicosanoids; Eosinophilic pneumonia; Leukotriene

Indexed keywords

11 EPIPROSTAGLANDIN F2 ALPHA; CARBON MONOXIDE; EOSINOPHIL PROTEIN X; GLUCURONIDE; LEUKOTRIENE B4; LEUKOTRIENE E4; NEUROTOXIN;

ADULT; AGED; ARTICLE; ASTHMA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; FEMALE; HUMAN; KIDNEY CONCENTRATING CAPACITY; LOEFFLER PNEUMONIA; LUNG CAPACITY; MALE; PRIORITY JOURNAL; REMISSION; ADOLESCENT; CASE CONTROL STUDY; INFLAMMATION; METABOLISM; MIDDLE AGED; URINE;

ADOLESCENT; ADULT; AGED; ASTHMA; CASE-CONTROL STUDIES; FEMALE; GLUCURONIDES; HUMANS; INFLAMMATION; LEUKOTRIENE E4; MALE; MIDDLE AGED; NEUROTOXINS; PULMONARY EOSINOPHILIA; REMISSION INDUCTION;

EID: 56149121293     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00093407     Document Type: Article

References (26)

1. Cottin V, Cordier JF. Eosinophilic pneumonias. Allergy 2005; 60: 841-857.
2. Allen J, Davis W. Eosinophilic lung diseases. Am J Respir Crit Care Med 1994; 150: 1423-1438.
3. Allen J, Pacht E, Gadek J, Davis W. Acute eosinophilic pneumonia as a reversible cause of noninfectious respiratory failure. N Engl J Med 1989; 321: 569-574.
4. Carrington C, Addington WW, Groff AM, et al. Chronic eosinophilic pneumonia. N Engl J Med 1969; 280: 787-798.
5. Kay AB, Menzies-Gow A. Eosinophils and interleukin-5: the debate continues. Am J Respir Crit Care Med 2003; 169: 1586-1587.
6. Kita H, Sur S, Hunt LW, et al. Cytokine production at the site of disease in chronic eosinophilic pneumonitis. Am J Respir Crit Care Med 1996; 153: 1437-1441.
7. Walker C, Bauer W, Braun RK, et al. Activated T cells and cytokines in bronchoalveolar lavages from patients with various lung diseases associated with eosinophilia. Am J Respir Crit Care Med 1994; 150: 1038-1048.
8. 2α content in bronchoalveolar lavage fluid obtained from patients with eosinophilic pneumonia. Chest 1987; 91: 204-206.
9. Parameswaran K, Cox G, Radford K, Janssen LJ, Sehmi R, O'Byrne PM. Cysteinyl leukotrienes promote human airway smooth muscle migration. Am J Respir Crit Care Med 2002; 166: 738-742.
10. Makoto N, Keiko S. The roles of cysteinyl leukotrienes in eosinophilic inflammation of asthmatic airways. Int Arch Allergy Immunol 2003; 131: 7-10.
11. Westcott JW, Taylor I. Measurement of leukotrienes from human biological fluids. In: Drazen JM, Dahlen SE, Lee TH, eds. 5-Lipoxygenase Products in Asthma. New York, Marcel Dekker, 1998; pp. 245-281.
12. Kristjansson S, Strannegard IL, Strannegard O, Peterson C, Enander I, Wennergren G. Urinary eosinophil protein X in children with atopic asthma: a useful marker of antiinflammatory treatment. J Allergy Clin Immunol 1996; 97: 1179-1187.
13. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma, Am Rev Respir Dis 1987; 136: 225-244.
14. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2006. www.ginasthma.com/Guidelineitem.asp??l1=2&l2=1&intId= 60 Date last accessed: May 2008.
15. Macintyre N, Crappo RO, Viegi G, et al. Standardisation of single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005; 26: 720-735.
16. Mita H, Oosaki R, Mizushima Y, Kobayashi M, Akiyama K. Efficient method for the quantitation of urinary leukotriene E4: extraction using an Empore C18 disk cartridge. J Chromatgr B Biomed Sci Appl 1997; 692: 461-466.
17. Higashi N, Taniguchi M, Mita H, Osame M, Akiyama K. A comparative study of eicosanoid concentrations in sputum and urine in patients with aspirin-intolerant asthma. Clin Exp Allergy 2002; 32: 1484-1490.
18. O'Sullivan S, Dahlén B, Dahlén SE, Kumlin M. Increased urinary excretion of the prostaglandin D2 metabolite 9α,11β- prostaglandin F2 after aspirin challenge supports mast cell activation in aspirin-induced airway obstruction. J Allergy Clin Immunol 1996; 98: 421-432.
19. Mita H, Turikisawa N, Yamada T, Taniguchi M. Quantification of leukotriene B4 glucuronide in human urine. Prostaglandins Other Lipid Mediat 2007; 83: 42-49.
20. Kumlin M. Measurements of leukotrienes in the urine: strategies and applications. Allergy 1997; 52: 124-135.
21. Macfarlane AJ, Dworski R, Sheller JR, Pavold ID, Kay AB, Barnes AC. Sputum cysteinyl leukotrienes increase 24 hours after allergen inhalation in atopic asthmatics. Am J Respir Crit Care Med 2000; 161: 1553-1558.
22. Brannan JD, Gulliksson M, Anderson SD, Chew N, Kumlin M. Evidence of mast cell activation and leukotriene release after mannitol inhalation. Eur Respir J 2003; 22: 491-496.
23. Lacoste JY, Bousquet J, Chanez P. Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. J Allergy Clin Immunol 1993; 92: 537-548.
24. Bousquet J, Chanez P, Lacoste JY. Eosinophilic inflammation in asthma. N Engl J Med 1990; 323: 1033-1039.
25. Ammit AJ, Songul SB, Johnson PR, Hughes JM, Armour CL, Black JL. Mast cell numbers are increased in the smooth muscle of human sensitized isolated bronchi. Am J Respir Crit Care Med 1997; 155: 1123-1129.
26. Epler GR, Mcloud TC, Gaensler EA, Mikus JP, Carrington CB. Normal chest roentgenograms in chronic diffuse infiltrative lung disease. N Engl J Med 1978; 298: 934-939.